Wegovy and Zepbound are the only drugs greenlighted by the FDA for only weight loss
194 GLP-1 also acts directly on the liver, inhibiting glycogenolysis, promoting glycogen synthesis, and regulating the expression of lipid metabolism-associated genes, thereby reducing hepatic fat accumulation and improving glucose and lipid homeostasis along the gutliver axis
From 2018 to 2023, the use of GLP-1 medications by bariatric patients evolved substantially
Several network meta-analyses have compared the efficacy of different GLP-1RAs.8587 Notably, the development of GLP-1RAs therapeutics is a rapidly evolving field, with novel agents, such as orforglipron, retatrutide, and cagriSema
Dual GLP-1/GIP Therapies Newer medications activate both GLP-1 and GIP hormone pathways
Enriched with diverse lipids, it protects the cell from desiccation